As MYC is often overexpressed in PDAC and has central roles in tumor maintenance [118,119], MYC may have utility either as a therapeutic target to improve therapeutic responses or a potential biomarker for PARP inhibitor sensitivity in PDAC tumors. Here, PARP1 is linked to neoplasm.